[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.62.139. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
November 26, 2008

Statin Therapy and Cognitive Deficits Associated With Neurofibromatosis Type 1

JAMA. 2008;300(20):2369-2370. doi:10.1001/jama.2008.687

To the Editor: Dr Krab and colleagues1 investigated the possible benefit of statin therapy in children with neurofibromatosis type 1 (NF1), a genetic disorder associated with learning disabilities.2 In this randomized, double-blind, placebo-controlled trial, it was found that simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, did not improve cognitive function in children with NF1.1 The motivation for this clinical trial came from the beneficial effect of lovastatin (another HMG-CoA reductase inhibitor) on cognitive function in the Nf1+/− mouse model NF1.3 These mice are heterozygous for a null mutation in neurofibromin, exhibit behavioral disorders that resemble those found in humans, and display deficits in physiological correlates of memory.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×